DENVER, CO / ACCESSWIRE / October 14, 2024 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced Josh ...
AQILION AB (publ) is developing the anti-inflammatory drug candidate AQ312 for the treatment of ulcerative colitis, and presents new results from the Aqilion preclinical development program at the ...